142 related articles for article (PubMed ID: 37257423)
1. Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study.
Ruiz-Salas V; Podlipnik S; Sandoval-Clavijo A; Sanmartin-Jiménez O; Bernia-Petit E; Bonfill-Ortí M; Bassas-Freixas P; Yebenes-Marsal M; Flórez-Menéndez Á; Solá-Ortigosa J; Just-Sarobé M; Aguayo-Ortiz R; Masferrer I Niubó E; Quintana-Codina M; Deza G; Jaka A; Fuentes MJ; Cañueto J; Toll A
Dermatology; 2023; 239(5):685-693. PubMed ID: 37257423
[TBL] [Abstract][Full Text] [Related]
2. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
5. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
[TBL] [Abstract][Full Text] [Related]
6. Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center.
Tong J; Mitchell B; Roth K; Logan D; Ernst S
J Cutan Med Surg; 2022; 26(2):143-148. PubMed ID: 34663118
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.
Cozzani R; Del Aguila R; Carrizo M; Sanchez S; Gonzalez A;
Int J Dermatol; 2020 May; 59(5):627-632. PubMed ID: 32034775
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
9. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
[TBL] [Abstract][Full Text] [Related]
10. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database.
Bassompierre A; Dalac S; Dreno B; Neidhardt EM; Maubec E; Capelle C; Andre F; Behal H; Dziwniel V; Bens G; Leccia MT; Meyer N; Granel-Brocard F; Beylot-Barry M; Dereure O; Basset-Seguin N; Mortier L
ESMO Open; 2021 Dec; 6(6):100284. PubMed ID: 34689002
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS.
Gutzmer R; Schulze HJ; Hauschild A; Leiter U; Meier F; Haferkamp S; Ulrich C; Wahl RU; Berking C; Herbst R; Häckl M; Schadendorf D
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1678-1685. PubMed ID: 33931910
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of response to vismodegib: a French study of 61 patients with multiple or locally advanced basal cell carcinoma.
Juzot C; Isvy-Joubert A; Khammari A; Knol AC; Nguyen JM; Dreno B
Eur J Dermatol; 2022 May; 32(3):401-407. PubMed ID: 36065537
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS.
Kaatz M; Mohr P; Livingstone E; Weichenthal M; Kreuter A; Pföhler C; Leiter U; Ulrich J; Utikal JS; Gutzmer R; Herbst R; Schadendorf D
Acta Derm Venereol; 2022 Apr; 102():adv00695. PubMed ID: 35199180
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib for periocular and orbital basal cell carcinoma.
Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology.
Juhasz ML; Marmur ES
J Drugs Dermatol; 2014 Jun; 13(6):729-33. PubMed ID: 24918565
[TBL] [Abstract][Full Text] [Related]
18. Experience With Vismodegib in the Treatment of Advanced Basal Cell Carcinoma at a Cancer Center.
Bernia E; Llombart B; Serra-Guillén C; Bancalari B; Nagore E; Requena C; Calomarde L; Diago A; Lavernia J; Traves V; Guillén C; Sanmartín O
Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):813-820. PubMed ID: 30055751
[TBL] [Abstract][Full Text] [Related]
19. Histologic Changes During Treatment With Vismodegib in Locally Advanced Basal Cell Carcinoma: A Series of 19 Cases.
Bancalari B; Llombart B; Serra-Guillén C; Bernia E; Requena C; Nagore E; Traves V; Calomarde L; Diago A; Guillén C; Sanmartín O
Am J Dermatopathol; 2019 Oct; 41(10):711-717. PubMed ID: 31436575
[TBL] [Abstract][Full Text] [Related]
20. Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease.
Schulze B; Meissner M; Ghanaati S; Burck I; Rödel C; Balermpas P
Strahlenther Onkol; 2016 Jan; 192(1):25-31. PubMed ID: 26449347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
